The Efficacy and Safety of Apatinib and Anlotinib in Advanced Non-Small Cell Lung Cancer
Anlotinib demonstrated greater efficacy and safety compared to apatinib in the treatment of advanced NSCLC, particularly in patients with bone metastases and EGFR(-).
Authors
- Hongxia Wang (ORCID: https://orcid.org/0000-0002-9820-9261)
- Qigang Dai (ORCID: https://orcid.org/0000-0001-7060-9821)
- Hui Wu (ORCID: https://orcid.org/0009-0007-6025-7181)
- Yun Zhao (ORCID: https://orcid.org/0009-0004-4994-3525)
- Qing Liu (ORCID: https://orcid.org/0000-0002-1663-189X)
- Yanan Liu (ORCID: https://orcid.org/0000-0003-2290-5380)
- Wenyue Yan
- Xiao Wei (ORCID: https://orcid.org/0009-0002-3370-6934)
- Yang Miao (ORCID: https://orcid.org/0000-0002-4127-2980)
- Xuyao Zhang (ORCID: https://orcid.org/0000-0003-1654-5550)
- Lei Huang (ORCID: https://orcid.org/0009-0007-0311-0773)
- Linlin Zhang (ORCID: https://orcid.org/0009-0006-8470-1868)
Institutions
- Nantong University (CN)
- Fudan University (CN)
- Jiangsu Provincial Center for Disease Control and Prevention (CN)
- Yancheng First People's Hospital (CN)
- Yancheng Second People's Hospital (CN)
Publication Details
- Journal
- OncoTargets and Therapy
- Published
- 2024-08-01
- DOI
- https://doi.org/10.2147/ott.s468932
- Citations
- 1
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- Bethune Charitable Foundation
- Jiangsu Pharmaceutical Association